TRDA vs. ANL, LXRX, SLRN, OCS, CRBP, FULC, TBPH, LRMR, PEPG, and TVTX
Should you be buying Entrada Therapeutics stock or one of its competitors? The main competitors of Entrada Therapeutics include Adlai Nortye (ANL), Lexicon Pharmaceuticals (LXRX), Acelyrin (SLRN), Oculis (OCS), Corbus Pharmaceuticals (CRBP), Fulcrum Therapeutics (FULC), Theravance Biopharma (TBPH), Larimar Therapeutics (LRMR), PepGen (PEPG), and Travere Therapeutics (TVTX). These companies are all part of the "pharmaceutical preparations" industry.
Entrada Therapeutics (NASDAQ:TRDA) and Adlai Nortye (NASDAQ:ANL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.
Adlai Nortye has lower revenue, but higher earnings than Entrada Therapeutics.
Entrada Therapeutics received 7 more outperform votes than Adlai Nortye when rated by MarketBeat users. However, 100.00% of users gave Adlai Nortye an outperform vote while only 73.33% of users gave Entrada Therapeutics an outperform vote.
In the previous week, Entrada Therapeutics had 7 more articles in the media than Adlai Nortye. MarketBeat recorded 7 mentions for Entrada Therapeutics and 0 mentions for Adlai Nortye. Entrada Therapeutics' average media sentiment score of 0.70 beat Adlai Nortye's score of 0.47 indicating that Entrada Therapeutics is being referred to more favorably in the media.
Entrada Therapeutics has a net margin of 14.42% compared to Adlai Nortye's net margin of 0.00%. Entrada Therapeutics' return on equity of 9.73% beat Adlai Nortye's return on equity.
Entrada Therapeutics currently has a consensus price target of $21.00, suggesting a potential upside of 40.09%. Adlai Nortye has a consensus price target of $30.00, suggesting a potential upside of 126.42%. Given Adlai Nortye's higher probable upside, analysts clearly believe Adlai Nortye is more favorable than Entrada Therapeutics.
86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are owned by institutional investors. 7.6% of Entrada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Entrada Therapeutics beats Adlai Nortye on 10 of the 12 factors compared between the two stocks.
Get Entrada Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TRDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Entrada Therapeutics Competitors List
Related Companies and Tools
